Dalrada Accelerates its National Healthcare Model with Acquisition of Watson Rx Solutions
09 Junio 2022 - 7:00AM
InvestorsHub NewsWire
SAN DIEGO, CA -- June
9, 2022 -- InvestorsHub NewsWire
-- Dalrada
Corporation (OTCQB: DFCO,
"Dalrada") announced today that it had acquired the pharmacy,
Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive
growth plans within the healthcare sector and paves the way for a
total end-to-end healthcare
solution.
Adding the 10-year-old
pharmacy to Dalrada Health’s comprehensive model expands the
subsidiary’s synergies with potential opportunities across its
products and services portfolio and offers another solution to meet
patient requirements.
Dalrada envisions a
comprehensive healthcare solution for all Dalrada Health clients
with unique offerings that will now include: a pharmacy to
facilitate prescription processing, physicians and clinicians at
treatment clinics, expanding into telemedicine, engagement of
Dalrada-owned testing facilities and laboratories, and utilization
of Company-specific technologies to facilitate immediate growth of
the business.
CEO and Founder, Brian
Bonar, states, “Watson Rx has a long history of providing excellent
pharmacy services. This acquisition allows Dalrada to expand its
healthcare footprint and continue to build a total health
management solution on an already successful turnkey operation. As
a result, the Company will be able to successfully address the
health needs of even more
patients.”
Through comprehensive
prescription management, education, nursing, and total health
management, Watson Rx Solutions' leadership team holds more than
six decades of combined experience in various complex pharmacy
disease states and retail services, always putting patients
first.
Dalrada plans on
entering the pharmaceutical space with an accelerated strategic
plan to leverage the Company’s existing capabilities. Research
reveals that the U.S. online and mail-order sales of drugs, health,
and beauty aids were valued at 75.5 billion USD in 2020.
Additionally,
- E-commerce
pharmaceutical sales and beauty aids increased from 51.7 billion
USD the year prior.
- Online, E-commerce,
and mail-order sales increased from around 31 to 38 percent during
the same period.
Pharmacy and drug
store sales reached 300 billion USD in 2020, with
over-the-counter (OTC) medication accounting for over 36
billion USD in sales during the same year, the highest-selling year
to date for the OTC segment. (Source: Statista U.S. online and
mail-order sales of drugs, health and beauty aids,
2003-2020).
Dalrada and its
subsidiaries provide value by making timely and impactful products
and services available within health, technology, and clean energy
markets. To learn more about how Dalrada Corporation continuously
creates innovative solutions to address the complex challenges of
today and the future, please visit www.Dalrada.com
and www.DalradaHealth.com.
About
Dalrada:
Dalrada Corporation
drives innovation that positively impacts people, businesses, and
the planet. With subsidiaries that are firmly positioned in the
world’s top three-growing industries of healthcare, clean energy,
and technology, Dalrada creates solutions that are sustainable,
affordable, and accessible.
The company works
continually to produce disruptive products and services that
accelerate positive change for current and future generations.
Dalrada’s global solutions directly address climate change,
post-pandemic gaps in the healthcare industry, and technology
solutions for a new era of human behavior and interaction, ensuring
a bright future for the world around
us.
Established in 1982,
Dalrada has since grown its footprint to include the unique
business divisions: Dalrada Health, Dalrada Precision, and Dalrada
Technologies. For more information, please visit
www.dalrada.com,
and follow us on Twitter,
Facebook, and LinkedIn.
Disclaimer:
Statements in this
press release that are not historical facts, the statements are
forward-looking, including statements regarding future revenues and
sales projections, plans for future financing, the ability to meet
operational milestones, marketing arrangements and plans, and
shipments to and regulatory approvals in international markets.
Such statements reflect management's current views, are based on
certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the
above forward-looking statements due to a number of important
factors and will be dependent upon a variety of factors including,
but not limited to, our ability to obtain additional financing that
will allow us to continue our current and future operations and
whether demand for our products and services in domestic and
international markets will continue to expand. The Company
undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the
date hereof or to reflect any change in the Company's expectations
regarding these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact the Company's success
are more fully disclosed in the Company's most recent public
filings with the US Securities and Exchange Commission ("SEC"),
including its annual report on Form
10-K.
Dalrada Financial (QB) (USOTC:DFCO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Dalrada Financial (QB) (USOTC:DFCO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024